Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Arthritis & Rheumatism

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1529-0131(200201)46:1<271::AID-ART10039>3.0.CO;2-CPMID 11817602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

  2001cited by this paper
• Immunobiology of vasoactive intestinal peptide (VIP)

  2000cited by this paper
• Anti‐inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock

  2000cited by this paper
• VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.

  1999cited by this paper
• VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells

  1999cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.

  1999cited by this paper
• Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun*

  1998cited by this paper
• In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.

  1994cited by this paper

• The p65-LOC727924-miR-26a/KPNA3-p65 regulatory loop mediates vasoactive intestinal peptide effects on osteoarthritis chondrocytes.

  2023cites this paper
• Vasoactive intestinal peptide alleviates osteoarthritis effectively via inhibiting NF-κB signaling pathway

  2018cites this paper
• Colonic levels of vasoactive intestinal peptide decrease during infection and exogenous VIP protects epithelial mitochondria against the negative effects of IFNγ and TNFα induced during Citrobacter rodentium infection

  2018cites this paper
• Protected Graft Copolymer Excipient Leads to a Higher Acute Maximum Tolerated Dose and Extends Residence Time of Vasoactive Intestinal Peptide Significantly Better than Sterically Stabilized Micelles

  2013cites this paper
• Nerve-Driven Immunity

  2012cites this paper
• Vasoactive Intestinal Peptide: Immune Mediator and Potential Therapeutic Agent

  2012cites this paper
• Vasoactive intestinal peptide signaling axis in human leukemia.

  2011cites this paper
• Local immunomodulatory gene therapy for Sjögren’s syndrome

  2010cites this paper
• Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

  2008cites this paper
• Exogenous VIP limits zymosan-induced generalized inflammation (ZIGI) in mice.

  2007cites this paper
• Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

  2007cites this paper
• Are Neuropeptides Important in Arthritis?

  2007cites this paper
• CHAPTER 5 – Vasoactive Intestinal Peptide: An Anti-inflammatory Neuropeptide

  2007cites this paper
• Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

  2007cites this paper
• The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: progress and future directions.

  2006cites this paper
• Analysing the effect of novel therapies on cytokine expression in experimental arthritis

  2005influential citation
• Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren’s syndrome

  2005cites this paper
• Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis

  2005cites this paper
• Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model.

  2005cites this paper
• Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis

  2005cites this paper
• Serotonin type 3 receptor antagonist tropisetron in the treatment of chronic inflammatory rheumatic conditions – preliminary clinical experience

  2004cites this paper
• The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?

  2004cites this paper
• The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  2004cites this paper
• Impact of cAMP on the T‐cell response to type II collagen

  2004cites this paper
• A recombinant adenoviral vector encoding functional vasoactive intestinal peptide.

  2004cites this paper
• Therapeutic approaches of vasoactive intestinal peptide as an immunomodulatory cytokine

  2004cites this paper
• Impact of VIP and cAMP on the regulation of TNF-α and IL-10 production: implications for rheumatoid arthritis

  2003influential citation